Metabolic Disease Candidate(s)
Type 2 Diabetes
Phase IIIActive
Key Facts
About China Resources Pharmaceutical Group
CR Pharma's mission is to serve as a foundational pillar of China's national healthcare system through its integrated pharmaceutical platform. Its key achievements include establishing one of the country's largest distribution networks, a significant manufacturing base, and an extensive retail pharmacy chain under the CRCare brand. The company's strategy is centered on vertical integration, leveraging its state-backed position to consolidate market share, control supply chains, and commercialize products from its R&D pipeline across key therapeutic areas. This approach aims to secure sustainable growth amid government-led volume-based procurement and an aging population.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Diabetes Management Gel | Gelteq Limited | Formulation Development |
| Tolimidone | Biodexa Pharmaceuticals | Phase 2 |
| Generic Semaglutide Injection (Obeda) | Dr. Reddy's Laboratories | Approved |
| BioChaperone® Lispro | Adocia | Phase 3 |
| BioChaperone® Combo (Insulin Glargine / Lixisenatide) | Adocia | Phase 2 |
| AJN003 (LuCI™) | AltrixBio | Pre-clinical |
| Hepatic Denervation for Type 2 Diabetes | Metavention | Feasibility |
| MVD-1 (SANA) | Eolo Pharma | Discovery |
| V-Go | MannKind | Approved |
| Type 2 Diabetes Management | iWel | Development |
| Band-assisted Duodenal Mucosal Resurfacing (DMR) | Endolastic | Pre-clinical |
| REMD-477 (Volagidemab) | REMD Biotherapeutics | Phase 2 (completed) |